Merck gets confirmatory trial win for Keytruda in endometrial cancerMerck & Co’s conditional FDA approval for checkpoint inhibitor Keytruda in endometrial cancer looks secure, thanks to a Share XMerck gets confirmatory trial win for Keytruda in endometrial cancerhttps://pharmaphorum.com/news/merck-gets-confirmatory-trial-win-for-keytruda-in-endometrial-cancer/
New era of genomic medicine begins as UK approves Lilly’s RetsevmoThe UK regulator has authorised Eli Lilly’s targeted cancer drug Retsevmo for tumours with RET fusion positive lung Share XNew era of genomic medicine begins as UK approves Lilly’s Retsevmohttps://pharmaphorum.com/news/uk-authorises-lillys-ret-targeted-retsevmo/
Merck & Co axes Keytruda lung cancer niche amid FDA crackdownMerck & Co has voluntarily withdrawn its Keytruda immunotherapy from a lung cancer niche in the US, amid Share XMerck & Co axes Keytruda lung cancer niche amid FDA crackdownhttps://pharmaphorum.com/news/merck-co-axes-keytruda-lung-cancer-niche-amid-fda-crackdown/
Merck takes on Lilly/Nektar in IL-2 with $1.85bn Pandion buyMerck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for Share XMerck takes on Lilly/Nektar in IL-2 with $1.85bn Pandion buyhttps://pharmaphorum.com/news/merck-takes-on-lilly-nektar-in-il-2-with-1-85bn-pandion-buy/
Sanofi’s immunotherapy Libtayo gets FDA approval in first line lung cancerSanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated Share XSanofi’s immunotherapy Libtayo gets FDA approval in first line lung cancerhttps://pharmaphorum.com/news/sanofis-immunotherapy-libtayo-gets-fda-not-in-first-line-lung-cancer/
Nektar lifted by Merck alliance for bempeg, new trial fundingNektar Therapeutics is waiting on multiple data readouts for its lead drug bempegaldesleukin paired with strategic partner Bristol-Myers Share XNektar lifted by Merck alliance for bempeg, new trial fundinghttps://pharmaphorum.com/news/nektar-lifted-by-merck-alliance-for-bempeg-new-trial-funding/
Guinea declares Ebola epidemic following first deaths since 2016Guinea has officially declared it is dealing with an Ebola epidemic, after at least three people died from Share XGuinea declares Ebola epidemic following first deaths since 2016https://pharmaphorum.com/news/guinea-declares-ebola-epidemic-following-first-deaths-since-2016/
Merck gets a leg-up for Keytruda in first-line kidney cancerNew phase 3 data have shored up the position of Merck & Co’s cancer immunotherapy Keytruda in the Share XMerck gets a leg-up for Keytruda in first-line kidney cancerhttps://pharmaphorum.com/news/merck-gets-a-leg-up-for-keytruda-in-first-line-kidney-cancer/
NICE backs NHS funding for MSD’s Keytruda combination in lung cancerNICE has backed regular NHS funding England and Wales for Merck, Sharp and Dohme’s Keytruda in combination with Share XNICE backs NHS funding for MSD’s Keytruda combination in lung cancerhttps://pharmaphorum.com/news/nice-backs-nhs-funding-for-msds-keytruda/
